Showing 2451-2460 of 3134 results for "".
- PRP Reduces Visible Signs of Facial Aginghttps://modernaesthetics.com/news/prp-reduces-visible-signs-of-facial-aging/2471993/Platelet-rich plasma (PRP) reduces the signs of aging on the face, according to the first randomized study of PRP. In the trial, 19 participants received PRP injections to one side of their face and a sham treatment with a saline solution to the other side. Six months afte
- ISAPS 2017: US Still Reigns As Cosmetic Surgery Capitol of the Worldhttps://modernaesthetics.com/news/isaps-2017-us-still-reigns-as-cosmetic-surgery-capitol-of-the-world/2471994/The USA, Brazil, Japan, Italy and Mexico continue to perform the most cosmetic surgery procedures across the globe, according to the 2017 statistics from the International Society of Aesthetic Plastic Surgery (ISAPS). These top five countries account f
- Cellfina Results Last Five Years, New Ultherapy Guidelineshttps://modernaesthetics.com/news/cellfina-results-last-five-years-new-ultherapy-guidelines/2472012/One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz
- BAAPS Calls for Brazilian Butt Lift Banhttps://modernaesthetics.com/news/baaps-calls-for-brazilian-butt-lift-ban/2472016/Due to the serious risks associated with the Brazilian butt lift, the British Association of Aesthetic Plastic Surgeons (BAAPS) is calling for a ban on the popular procedure until more data can be collected. The procedure is known to have the highest death rate of all cosmetic surger
- Introducing Juvéderm It, Allergan's Newest Ad Campaignhttps://modernaesthetics.com/news/introducing-juvderm-it-allergans-newest-ad-campaign/2472020/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- RealSelf: One in Three U.S. Adults are Considering Nips/Tuckshttps://modernaesthetics.com/news/realself-one-in-three-us-adults-are-considering-nipstucks/2472025/One in three adults (37 percent) in the U.S. are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the
- ASDS 2018 Survey: Close to 70 percent of Consumers Thinking About Cosmetic Treatmentshttps://modernaesthetics.com/news/asds-2018-survey-close-to-70-percent-of-consumers-are-thinking-about-cosmetic-treatments/2472034/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmeti
- Allergan Shares Results of Higher Dose Botox Cosmetic for the Treatment Glabellar Lineshttps://modernaesthetics.com/news/allergan-share-results-of-higher-dose-botox-cosmetic-for-the-treatment-glabellar-lines/2472035/Allergan plc clinical study results of higher doses of Botox Cosmetic compared to Botox Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan conducted this trial to evaluate the duration of effect and safety of Botox
- Candela Acquires Ellipsehttps://modernaesthetics.com/news/candela-acquires-ellipse/2472039/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita